Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CorMedix Provides Update On CE Marking Process For Neutrolin

RELATED NEWS
Trade CRMD now with 

CorMedix Inc. (CRMD: Quote) on Thursday announced the receipt of a request for additional information and data, including six month stability data on the third and final test batch from TUV-SUD and MEB-Netherlands on the CE Mark application for Neutrolin in the EU.

Upon delivery of the requested information, the company believes that Neutrolin will enter a third and final round of review to finalize the CE Mark.

CorMedix anticipates providing such additional information and data in late third quarter or early fourth quarter of 2012.

As a result, CorMedix now expects a final review and determination regarding its CE Mark application by the end of 2012.

CorMedix said it is currently in the final stages of completing its commercialization plan and is in talks with several potential partners regarding the launch of Neutrolin in Europe.

Based on the status of such talks CorMedix continues to target a commercial launch for fourth quarter of 2012 or first quarter of 2013.

Click here to receive FREE breaking news email alerts for CorMedix Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.